NCCN’s Myeloma MRD Update Spotlighting clonoSEQ Could Be A Game Changer For Adaptive Biotechnologies (ADPT)

• Adaptive Biotechnologies recently highlighted updates to the National Comprehensive Cancer Network multiple myeloma guidelines, which now feature a dedicated page on minimal residual disease testing and specifically reference its FDA-cleared clonoSEQ assay with preferred high-sensitivity thresholds and expanded testing timepoints.

• The inclusion of clonoSEQ by name, alongside broader recommendations for routine and longitudinal MRD assessment, strengthens its position as a standardized tool in myeloma care and could influence how often clinicians order this test across a patient's treatment journey.

• We'll now examine how clonoSEQ's explicit inclusion and expanded MRD testing recommendations may shape Adaptive Biotechnologies' broader investment narrative.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 19 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

Adaptive Biotechnologies Investment Narrative Recap

To own Adaptive Biotechnologies, you need to believe MRD becomes a routine part of blood cancer care and that clonoSEQ remains a leading, billable test within that workflow. The NCCN multiple myeloma update that names clonoSEQ and expands recommended MRD timepoints supports the near term volume and reimbursement catalyst, but it does not remove the central risk that company wide losses and cash burn could still leave investors exposed to future dilution or deeper cost cuts.

Among recent developments, the June 2026 announcement that Adaptive is exploring a separation of its MRD and Immune Medicine businesses is especially relevant here. If MRD is carved out as a more focused, testing centric company just as guidelines formally embed high sensitivity MRD in myeloma care, that structural change could interact directly with the core catalyst of recurring clonoSEQ volumes and the ongoing risk of prolonged unprofitability at the consolidated level.

Yet, even with growing clonoSEQ momentum, investors should be aware that prolonged losses and potential dilution risk could still...

Read the full narrative on Adaptive Biotechnologies (it's free!)

Adaptive Biotechnologies' narrative projects $491.4 million revenue and $18.5 million earnings by 2029. This requires 16.8% yearly revenue growth and an earnings increase of about $82.4 million from -$63.9 million today.

Uncover how Adaptive Biotechnologies' forecasts yield a $26.36 fair value , a 5% downside to its current price.